Project description:Serum samples were obtained from patients with ovarian cancer (OC; n=64) and noncancerous control (n=4) for microarray. We found that four miRNAs were significantly high-expression level in OC relative to the controls.
Project description:Exosomes were purified from 250 ul serum using ExoQuickTm. The presence of particles consistent in size with exosomes (60-150nm) was confirmed using a Nanosight LM10. miRNA was extracted from exosomes using an miRNeasy Serum/Plasma kit (Qiagen, #217184). miRNA was reversed transcribed using a TaqMan® microRNA Reverse Transcription Kit (Life technologies, #4366596). miRNA profiling was performed with a high throughput TaqMan® OpenArray® Human microRNA panel (Life technologies, #4461104). The panel consisted of probes for 754 human miRNAs that are based on miRNA sequences derived from Sanger miRBase v14. MegaplexTM Primer Human Pool A v2.1 and Human Pool B v2.0 or v3.0 The poor prognosis and rising incidence of oesophageal adenocarcinoma highlight the need for improved methods for detection of this cancer. Molecular biomarkers offer potential for this. The potential for circulating miRNAs as biomarkers in some other cancers has been shown, but circulating miRNAs have not been well characterized in oesophageal adenocarcinoma. This study investigated whether circulating miRNAs could be used to detect oesophageal adenocarcinoma.
Project description:This SuperSeries is composed of the following subset Series: GSE32037: Identification of potential biomarkers for patients with neurodegenerative parkinsonian syndromes using serum cytokine microarray analysis; series 6 GSE32039: Identification of potential biomarkers for patients with neurodegenerative parkinsonian syndromes using serum cytokine microarray analysis; series 7 GSE32040: Identification of potential biomarkers for patients with neurodegenerative parkinsonian syndromes using serum cytokine microarray analysis; series 8 Refer to individual Series
Project description:Purpose: Idenfication of microRNA biomarkers of Chronic wasting disease in serum from infected elk Methods: Illumina next generation was used to profile abundance of serum miRNA in elk naturally infected with chronic wasting disease and Hamsters experimentally infected with the 263K scrapie prion strains Results: A signature of 21 miRNAs with diagnostic potential was found to be altered in abundance in serum from CWD infected elk. Of these, 6 were similarily altered in the serum from the 263K infected hamsters Conclusion: These altered miRNA signatures may serve as the basis for non-invasive diagnostic assays for chronic wasting disease and may shed light on the pathogenesis of prion infection
Project description:In this pilot study, we analyzed serum microRNA profiles of subjects with post-traumatic stress disorders in order to determine their potential to be used as diagnostic biomarkers. We discovered that serum microRNAs could potentially serve as diagnostic biomarkers of PTSD, both individually or grouped within a cluster of co-expressed miRNAs.
Project description:This dataset contains serum proteomic data from patients with primary ovarian insufficiency (POI), individuals with natural menopause, and healthy controls, analyzed by label-free quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS). The study aims to identify differentially expressed proteins associated with POI, explore potential biomarkers and molecular mechanisms of the disease, and provide new evidence for the diagnosis and treatment of POI.
Project description:Global microRNA expression profiling of serum were collected using Agilent miRNA microarrays (G4471A Human, Amadid 29297, Sanger 14) carrying 887 individual human miRNA probes. Two different sources of RNA were analyzed: serum from healthy controls (N=5) and patients with ovarian carcinoma (CA, n=5)